MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $1.03B
• Dividend Yield: N/A
• Average Volume (3M): 655.26K
• Price to Earnings (P/E): 25.1
• Beta (1Y): 0.84
• Revenue Growth: 5.34%
• EPS Growth: -50.52%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 147,702,130
• 10 Day Avg. Volume: 873,001
• 30 Day Avg. Volume: 655,265
• PEG Ratio: -7.04
• Price to Book (P/B): 4.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.80
• Price Target Upside: 62.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 75 Outperform
• Price Target: $8.00 ▲(20.12%Upside)

MiMedx Group's strong financial performance and strategic initiatives provide a solid foundation for future growth. However, technical indicators suggest caution due to potential overbought conditions. Valuation concerns and segment-specific challenges also temper the outlook. The company's strategic focus and positive earnings call sentiment are supportive factors for the stock.

Positive Factors

Market Share

MDXG's status as a good actor with strong products on approved Skin Substitute lists driving steady market share gains once LCD policies shift.

Product Sales

MDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.

Negative Factors

Reimbursement Uncertainty

Continuing reimbursement uncertainty disrupted the business in the physician office setting.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

How the Company Makes Money

MiMedx Group generates revenue primarily through the sale of its placental-based tissue products. These products are marketed to hospitals, clinics, and healthcare professionals who use them in treating chronic and acute wounds, as well as in surgical and sports medicine applications. The company has established partnerships with healthcare providers and distributors to expand its market reach and enhance product accessibility. Key revenue streams include direct sales to medical facilities and distribution agreements with third-party partners. Additionally, MiMedx invests in research and development to innovate and expand its product offerings, which can lead to new revenue opportunities in emerging therapeutic areas.

MiMedx Group Financial Statement Overview

Summary

MiMedx Group has shown strong growth in revenue and profitability, with a positive net profit margin and robust cash flow. The solid balance sheet with low leverage supports financial stability, though opportunities to leverage cash reserves more effectively could boost growth.

Income Statement

MiMedx Group has shown strong growth in revenue over the observed periods, with a notable increase from $267.8M in 2022 to $352.4M in TTM (Trailing-Twelve-Months) 2025. Gross profit margin is robust at 81.9% for TTM, indicating efficient cost management. The net profit margin has turned positive, reaching 11.4% in TTM 2025 from negative figures in previous years, signaling improved profitability. However, the decline in EBIT from 2024 to TTM 2025 suggests some operational cost challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 74.98% in TTM 2025, indicating a strong capital structure. The debt-to-equity ratio is very low at 0.01, showcasing minimal leverage, which reduces financial risk. Return on equity is positive at 19.81%, reflecting efficient use of equity to generate profits. Nonetheless, the high level of cash reserves relative to debt suggests missed opportunities for investment or growth.

Cash Flow

MiMedx Group demonstrates strong cash flow generation with free cash flow growing significantly, highlighted by a free cash flow of $68.7M in TTM 2025. The operating cash flow to net income ratio is favorable, indicating efficient cash generation from operations. Furthermore, the free cash flow to net income ratio of 1.71 signifies robust cash conversion efficiency. Overall, the cash flow position is solid, underpinning financial stability and flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	352.38M	348.88M	321.48M	267.84M	258.62M	248.23M
Gross Profit	288.54M	288.81M	266.84M	219.53M	215.33M	208.90M
EBITDA	54.95M	64.34M	40.52M	-10.69M	-1.89M	-45.76M
Net Income	40.18M	42.42M	67.44M	-30.20M	-10.29M	-49.28M
Balance Sheet
Total Assets	270.42M	263.92M	239.05M	171.43M	187.93M	202.03M
Cash, Cash Equivalents and Short-Term Investments	106.43M	104.42M	82.00M	65.95M	87.08M	95.81M
Total Debt	18.66M	18.83M	48.10M	48.59M	48.13M	47.70M
Total Liabilities	67.64M	70.81M	96.33M	189.42M	187.85M	202.18M
Stockholders Equity	202.78M	193.11M	142.72M	-17.99M	82.00K	-150.00K
Cash Flow
Free Cash Flow	68.32M	64.52M	24.79M	-20.58M	-5.45M	-34.82M
Operating Cash Flow	67.55M	66.20M	26.77M	-17.89M	-1.98M	-30.26M
Investing Cash Flow	-3.96M	-9.58M	-2.15M	-2.66M	-3.40M	-4.55M
Financing Cash Flow	-3.61M	-34.20M	-8.57M	-580.00K	-3.35M	61.56M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.66
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Neutral. The current price of 6.66 is above the 20-day moving average (MA) of 6.21, above the 50-day MA of 6.53, and below the 200-day MA of 7.50, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 57.43 is Neutral, neither overbought nor oversold. The STOCH value of 78.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	75 Outperform	$1.03B	25.14	22.29%	―	5.34%	-50.52%
ARDX	64 Neutral	$1.10B	―	-36.26%	―	127.33%	21.31%
IOVA	53 Neutral	$664.53M	―	-51.85%	―	11070.12%	32.07%
CLDX	52 Neutral	$1.49B	―	-23.20%	―	24.49%	5.14%
OCUL	51 Neutral	$1.71B	―	-57.19%	―	-0.33%	-3.59%
Sector *	49 Neutral	AU$2.50B	3.30	-57.47%	2.80%	36.73%	13.67%
LQDA	47 Neutral	$1.15B	―	-188.03%	―	-11.42%	0.26%

MiMedx Group Corporate Events

MiMedx Group Holds Annual Shareholder Meeting

On June 18, 2025, MiMedx Group held its Annual Meeting of Shareholders, where 85.7% of the voting shares were represented. During the meeting, nine directors were re-elected, an advisory resolution on executive compensation was approved, Deloitte & Touche LLP was ratified as the independent auditor for 2025, an amendment to the 2016 Equity and Cash Incentive Plan was approved, and it was decided that the advisory vote on executive compensation would occur annually.

The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

MiMedx Group Highlights Growth at Healthcare Conference

MiMedx Group announced its participation in the Bank of America Securities 2025 Healthcare Conference, highlighting its updated investor presentation. The company is poised for growth with expectations of expanding its product portfolio and increasing its presence in surgical settings, driven by favorable market trends and innovative placental-derived products. The announcement underscores MiMedx’s strategic focus on expanding its global footprint and enhancing its product offerings to drive profitability and stakeholder value.

The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

MiMedx Group Reports Q1 2025 Financial Results

On April 30, 2025, MiMedx Group announced its first quarter financial results, reporting net sales of $88 million, a 4% increase year-over-year, driven by significant growth in surgical products. Despite a decline in wound product sales and a decrease in gross margin, the company maintained a strong adjusted EBITDA margin of 20%. CEO Joseph H. Capper highlighted the company’s strategic efforts to address challenges in the Medicare landscape and expand their product pipeline, including the introduction of CELERA™. MiMedx remains focused on long-term growth, expecting high single-digit sales growth for 2025 and low double-digit growth in subsequent years.